2026-10-21 20:04:55 UTC#495663newconfirmednews
FDMT stock news
FDMT stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire12 wire items
2026-10-06 12:36:00 UTC#419467newconfirmednews
Chardan Capital maintains Buy rating on 4D Molecular Therapeutics (FDMT)
dow_jonesimportance 0.30trust 0.604D Molecular Therapeutics, Inc. +0.20Chardan Capital Markets, LLC +0.20
2026-09-28 12:13:27 UTC#377396updateconfirmednews
4D Molecular Therapeutics begins 4SIGHT Phase 3 enrollment; SPECTRA 2-year data shows 61% injection reduction
tradingviewimportance 0.50trust 0.704D Molecular Therapeutics, Inc. +0.504D-150 +0.504SIGHT +0.40+2 entities
2026-09-28 12:00:00 UTC#377269newconfirmedpress release
4D Molecular Therapeutics initiates 4SIGHT Phase 3 trial of 4D-150 for diabetic macular edema
globenewswireimportance 0.60trust 0.904D Molecular Therapeutics, Inc. +0.604D-150 +0.604SIGHT +0.50+2 entities
2026-09-14 23:02:00 UTC#310613duplicateconfirmednews
4D Molecular Therapeutics (FDMT) 4D-150 gene therapy shows two-year safety and efficacy in retinal disease trials
quartrimportance 0.30trust 0.504D Molecular Therapeutics, Inc. +0.604D-150 +0.60Otsuka Pharmaceutical Co., Ltd. +0.50
2026-09-14 22:38:09 UTC#310552newreportednews
4D Molecular Therapeutics (FDMT) reports 4D-150 clinical progress in wet AMD and DME, outlines commercial readiness
2026-09-14 11:12:00 UTC#306678newconfirmednews
4D Molecular Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald, price target set at $20
dow_jonesimportance 0.30trust 0.704D Molecular Therapeutics, Inc. +0.50Cantor Fitzgerald, L.P. +0.50
2026-08-13 21:32:46 UTC#174778newconfirmednews
4D Molecular Therapeutics Q2 adjusted loss $1.04/share vs $1.02/share est, revenue $3.78M vs $3.10M est
2026-08-06 10:00:00 UTC#136159newconfirmednews
Upcoming US Earnings Calendar: 10x Genomics, ACI Worldwide, and Others Scheduled for Thursday
dow_jonesimportance 0.30trust 0.9010x Genomics, Inc. 04D Molecular Therapeutics, Inc. 0Abacus Global Management, Inc. 0+2 entities
2026-07-31 16:02:00 UTC#110636newconfirmednews
B. Riley Securities initiates coverage of 4D Molecular Therapeutics with Buy rating
dow_jonesimportance 0.30trust 0.804D Molecular Therapeutics, Inc. +0.40B. Riley Securities, Inc. +0.20
2026-07-18 19:20:47 UTC#49129duplicateconfirmednews
4D Molecular Therapeutics reports positive 2-year PRISM trial data for 4D-150 in wet AMD
2026-07-18 19:15:00 UTC#49128newconfirmedpress release
4D Molecular Therapeutics reports positive 2-year data for 4D-150 gene therapy in wet AMD trial
globenewswireimportance 0.60trust 0.904D Molecular Therapeutics, Inc. +0.704D-150 +0.70PRISM +0.50+2 entities